Revelations 13:14 “…by the signs that it is allowed to work in the presence of the beast it deceives those who dwell on earth…”
Important Takeaways:
- Forget college essays. Artificial intelligence has much bigger fish to fry.
- Biotech firm Insilico Medicine said Monday that it entered an “AI-discovered-and-designed” drug into Phase 2 clinical trials involving human subjects, a first for the industry. The robots: they may not be so bad after all.
- The sheer data-crunching and protein-identifying prowess of such systems could potentially cut development time in half, and development prices by even more, proponents often claim. In plain English: AI can complete complex math problems far faster than human scientists ever could. Thus, AI and ML tools could help develop 50 new drugs worth potentially $50 billion over the next decade, according to a Morgan Stanley report.
- The entire industry has already bet big on AI start-ups like Insilico:
- Investment in AI-led drug discovery hit roughly $25 billion in 2022, according to research firm Deep Pharma Intelligence, roughly triple what it was four years earlier. That contrasts with a nearly 37% year-over-year decline in VC investment in US and Europe biotech firms in 2022, according to EY.
- “Every major pharma company has invested in partnerships with at least one, if not multiple, AI companies,” Eric Topol, Scripps Research Translational Institute founder and director, told the FT.
Read the original article by clicking here.
